Introduction
============

Recent guidelines for Alzheimer\'s disease diagnosis (AD) called for increased use of AD biomarkers during presymptomatic and symptomatic phases.[@b1]--[@b3] Cerebrospinal fluid (CSF) levels of *β*-amyloid 1--42 (A*β*42), total tau (T-tau), and tau phosphorylated at threonine 181 (p-tau~181~) represent such biomarkers, and altered levels of these biomarkers are highly associated with future conversion to dementia due to AD pathology.[@b4]--[@b6] Studies using ante-mortem CSF samples from subjects followed longitudinally to autopsy showed that CSF A*β*42 is sensitive for AD,[@b7],[@b8] CSF t-Tau is specific for AD, and the ratio of CSF t-Tau to A*β*42 (t-Tau/A*β*42) appears to strike a balance between sensitivity and specificity. Despite ongoing international standardization efforts,[@b9],[@b10] variability in measured biomarker levels persists even after accounting for reagent-related factors. It remains also unclear why subtle interoperator differences can result in significant measurement imprecision. During a two-site standardization process, we discovered that CSF A*β*42 measured using the Alzheimer\'s Disease Neuro-imaging Initiative (ADNI) protocol captures only a fraction of the total measurable CSF A*β*42, and this apparent A*β*42 is further influenced by technical factors and other CSF proteins implicated in AD.[@b11]--[@b13] We then identified values equivalent to published ADNI thresholds for diagnosis based on processing techniques, and experimentally determined how Ab-binding proteins directly influenced the relative measured A*β*42 levels.

Methods
=======

Participants
------------

Consecutive patients and control subjects were recruited and longitudinally followed in the Emory Cognitive Neurology Clinic or the Emory Alzheimer\'s Disease Research Center (ADRC). The study was approved by the Emory University Institutional Review Board, and informed consent was obtained from all patients or their authorized representatives. Participants (*n* = 140) included community-dwelling healthy volunteers with normal cognition and cognitively impaired patients evaluated at subspecialty clinics dedicated to the evaluation of neurodegenerative disorders including mild cognitive impairment (MCI),[@b14] AD,[@b15],[@b16] frontotemporal dementia (FTD),[@b17] dementia with Lewy bodies (DLB),[@b18] as well as potentially reversible causes such as normal pressure hydrocephalus ([Data S1](#sd1){ref-type="supplementary-material"}). All subjects underwent standardized neuropsychological analysis, and memory and executive functions were analyzed using *Z*-scores. A memory *Z*-score was derived by averaging the *Z*-scores of Consortium to Establish a Registry for Alzheimer\'s Disease (CERAD) word list learning and delayed word list recall.[@b19],[@b20] An executive *Z*-score was derived by averaging the *Z*-scores of Trail Making Part B, letter-guided fluency, and reverse digit span. *APOE* genotyping was performed on all but four participants in this study.

Procedures
----------

Samples were collected from subjects according to strict protocols. At collection, participants were ≥21 years of age and in good general health, having no other psychiatric or major medical diagnoses that could contribute significantly to cognitive impairment or dementia other than the primary neurodegenerative disorder. CSF samples were collected between 8 [am]{.smallcaps} and 2 [pm]{.smallcaps} without overnight fasting and immediately aliquoted before freezing, although otherwise we used the ADNI biofluid protocols.

Four different protocols were evaluated at baseline for CSF AD biomarker measurements, including three protocols using never-thawed samples and one protocol using never-frozen samples (Fig.[1A](#fig01){ref-type="fig"}):ADNI: Aliquots were allowed to thaw at room temperature for 30 min before each sample was vortexed for 15 sec until all samples in a given analytical run were vortexed. Immediately before loading into a 96-well plate, each aliquot was re-vortexed for 2 sec.Vortex: Processed the same way as ADNI samples, except each aliquot was vortexed vigorously for 15 sec immediately before loading into 96-well plates.Centrifuge: Based on the difference in measured AD biomarkers between the ADNI and Vortex protocols (Fig.[1A](#fig01){ref-type="fig"}), we hypothesized that some AD-related peptides become undetectable through the ADNI protocol by settlement or aggregation, and this process can be reproduced by centrifuging CSF samples. Following thawing (30 min) and vortexing (15 sec), CSF samples were centrifuged (21,130 × g for 15 min) in a tabletop centrifuge. The top 200 *μ*L of CSF was saved for AD biomarker analysis. Immediately before loading onto 96-well plates, each aliquot was vigorously re-vortexed (15 sec).Warm: To determine whether the difference in AD biomarker levels between the ADNI and Vortex protocols can result from ex vivo freezing of CSF, never-frozen CSF aliquots were transferred into a 37°C water bath immediately after lumbar puncture and centrifuged as above. The top 200 *μ*L of CSF was saved for AD biomarker analysis, and each sample was vortexed vigorously (15 sec) prior to assay plate loading.

![Measured CSF A*β*42 levels are influenced by preanalytical processing and disease status. (A) Four distinct preanalytical protocols lead to different measured A*β*42 levels. All values are represented as percent of biomarker levels measured per total protocol (±standard deviation) to account for interindividual differences in biomarker levels. "ADNI" is the standard protocol involving no centrifugation and limited vortexing immediately prior to plate loading. "Vortex" represents total measurable CSF A*β*42 with vigorous vortexing for 15 sec prior to assay plate loading. "Centrifuge" represents the fraction of CSF A*β*42 detectable after "Total" samples were centrifuged for 15 min and the top 200 *μ*L was analyzed. "Warm" represents a variation of the centrifuge protocol, except CSF aliquots are kept at 37°C immediately after lumbar puncture and processed for biomarker analysis within 2 h after lumbar puncture. \**P* \< 0.001 compared to Total A*β*42 levels by Mann--Whitney *U*-test. (B) Comparison of AD biomarker levels (derived from ADNI/centrifuge protocols) as percentages of total levels according to diagnosis (NC, normal cognition; MCI, mild cognitive impairment; AD, Alzheimer\'s disease; OD, other non-AD dementia). Boxplots show minimum, first quartile, median, third quartile, and maximum values as well as outliers (small circles). \*\**P* \< 0.019 by Mann--Whitney *U*-test. CSF, cerebrospinal fluid; ADNI, Alzheimer\'s disease neuro-imaging Initiative.](acn30002-0131-f1){#fig01}

CSF levels of AD biomarkers (A*β*42, total tau, and p-tau~181~) were measured using the multiplex xMAP Luminex platform (Luminex Corp, Austin, TX) with AlzBio3 kits (Innogenetics, Ghent, Belgium). To characterize the differences between the four protocols, CSF from 15 subjects (three aliquots per subject) were immediately frozen and kept at −80°C until further analysis. All three aliquots were analyzed in duplicates after processing (ADNI, vortex, and centrifuge) on consecutive assay plates using the same kit lot. Samples from the same subject, regardless of manipulation, were analyzed next to each other to minimize intra- or interplate variability. For the "Warm" protocol, one CSF aliquot from each subject was kept at 37°C immediately after collection without freezing, and analyzed that afternoon in conjunction with an adjacent aliquot that was frozen earlier that morning and processed according to the vortex protocol. Thus, each subject in the "Warm" protocol was tested in a separate assay plate using the same kit lot, and a percentage was calculated based on the vortex and warm results from that day.

Because ADNI and Centrifuge protocols gave rise to similar AD biomarker levels, we collectively referred to the measured A*β*42 via ADNI and centrifuge protocols as suspended A*β*42 (susA*β*). For the larger cohort (*n* = 140), CSF biomarkers from vortex and centrifuge protocols within the same subject were analyzed in duplicates on the same plate in adjacent wells, with different plates using reagents from the same kit lot.

Replication of distinct CSF Aβ42 pools
--------------------------------------

Duplicate aliquots of CSF from 20 Emory subjects were sent to University of Pennsylvania on dry ice overnight, and CSF was processed according to Emory protocol to derive suspended and total measurable CSF A*β*42 levels. CSF % susA*β* (calculated by dividing susA*β* by total measurable A*β*42) was independently determined and then compared with values from Emory. To replicate level differences between susA*β* and total measurable A*β*42, CSF samples were further analyzed by western blotting using a modified bicine/bistris/tris/sulphate sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) protocol ([Data S1](#sd1){ref-type="supplementary-material"}).[@b21]

Other CSF proteins that influence % susAβ
-----------------------------------------

A*β*42 is known to interact with other proteins including apoJ,[@b22] apolipoprotein E (apoE),[@b23],[@b24] and *α*-synuclein.[@b25]--[@b27] To determine whether susA*β* levels are influenced by these interacting proteins, we measured their levels in 69 subjects chosen from the larger cohort ([Data S1](#sd1){ref-type="supplementary-material"}). These subjects were randomly selected and were similar to the unselected subjects in terms of age, gender, disease duration, and CSF AD biomarker levels (data not shown). Levels of A*β*-interacting proteins as well as total CSF AD biomarkers were entered into a multivariate linear regression model to determine the strongest factors predicting susA*β* levels and % susA*β*.

Furthermore, we analyzed whether increasing levels of A*β*42-interacting proteins would alter % susA*β*. Because we found apoJ to strongly correlate with % susA*β*, we first determined the time-dependent effect of increasing apoJ levels. Five CSF aliquots were selected from each of five patients with low baseline % susA*β* (median 34%, range 32--49%), and the time-dependent effect of apoJ on % susA*β* was determined ([Data S1](#sd1){ref-type="supplementary-material"}). We additionally tested the effects of increasing apoJ, apoE (Millipore, Billerica, MA; apoE includes a combination of isoforms), albumin (Jackson ImmunoResearch Laboratories, West Grove, PA), and *α*-synuclein (rPeptide, Bogart, GA) on % susA*β* after 4 hr of incubation at 37°C in 12 subjects (mean % susA*β* of 58.9%, SD 20.8%). Each protein was increased by its level difference between the top and bottom quartiles of % susA*β*. Treatment-dependent % susA*β* was calculated for each time point, and then normalized to the baseline buffer-treated % susA*β*.

Statistical analysis
--------------------

Statistical analysis was performed in IBM-SPSS 20 (Chicago, IL). For baseline comparison, chi-squared test was used to analyze categorical variables, and analysis of variance (ANOVA) was used to compare continuous variables. ANOVA was used to determine whether subjects from the four diagnostic groups differed in % susA*β*, and Pearson correlational analysis was used to determine the association between % susA*β* and memory and executive dysfunctions (*Z*-scores). Linear regression model was then used to analyze the relationship between susA*β* levels (or % susA*β*) and other factors (including age, gender, presence of APOE4 allele, total measurable A*β*42 levels, t-Tau, p-Tau~181~, apoE, and apoJ). Mixed linear analysis was used to determine the effect of apoJ addition to the time-dependent % susA*β* over 72 h. Because % susA*β* reaches an asymptote, time (h) was log transformed for the purpose of calculating the slope before used as a fixed variable as well as a random variable to determine the effect of apoJ addition.

Results
=======

CSF susAβ represents half of total measurable CSF Aβ42
------------------------------------------------------

We first measured CSF AD biomarker levels in three CSF aliquots from the same CSF draw that were processed according to the ADNI, vortex, and centrifuge protocols. Total measurable CSF A*β*42 levels were significantly higher than those measured using the ADNI protocol (Fig.[1A](#fig01){ref-type="fig"}), which led us to test manipulations which can potentially replicate (centrifuge) this difference. In keeping with our hypothesis, A*β*42 levels were indistinguishable between the ADNI and centrifuge protocols. Because ADNI samples were never centrifuged, we considered the CSF A*β*42 levels from these two protocol to reflect the pool of A*β*42 that remains suspended (susA*β*) in solution after table-top incubation (at room temperature) or centrifugation (Fig.[2](#fig02){ref-type="fig"}). Using the entire cohort of subjects (*n* = 140, Table[1](#tbl1){ref-type="table"}), susA*β* levels, on average, represented 57.0% of total A*β*42 levels (SD = 16.6%, *P* \< 0.001), and correlated moderately with total measurable A*β*42 levels (*R* = 0.818, *P* \< 0.001, Fig.[3](#fig03){ref-type="fig"}). Subjects with clinical AD had lower % susA*β* than subjects with normal cognition, MCI, or non-AD dementia (*P* \< 0.017 by Mann--Whitney *U*-test, Fig.[1B](#fig01){ref-type="fig"}). This association persisted (*F* = 9.235, *P* = 0.003) even when adjusting for age, gender, and total A*β*42. When subjects with normal cognition, MCI, and AD were analyzed, % susA*β* is inversely correlated with memory *Z*-scores (*P* = 0.002) and executive *Z*-scores (*P* = 0.005). Subtracting susA*β* level from total measurable A*β*42 level generated a value that did not differ across categories. Paired *T*-tests also showed suspended t-Tau and p-Tau~181~ levels to be lower than total measurable t-Tau and p-Tau~181~ levels (*P* \< 0.001 for both), but the difference in levels (15.3 ± 16.5% for t-Tau, 12.4 ± 20.9% for p-Tau~181~) is much smaller than that seen for A*β*42 and there was no difference across clinical categories. Thus, we hereafter focused on susA*β* and factors which influence this measure.

![Western blot showing cerebrospinal fluid (CSF) A*β*42 peptides generated through vortex (V) and centrifuge (C) protocols. Parallel CSF samples from two subjects with Alzheimer\'s disease (AD) and two subjects with normal cognition (NC) were treated by each protocol and then analyzed on urea-containing SDS gel to separate A*β*40 and A*β*42. Each CSF sample from the vortex protocol had higher A*β*42 levels than the corresponding sample from the centrifuge protocol.](acn30002-0131-f2){#fig02}

###### 

Baseline demographic and biomarker features of the Emory cohort

                                        Normal cognition (*n* = 30)   MCI (*n* = 36)   AD (*n* = 36)   Other dementia (FTD, LBD, NPH; *n* = 38)   *P*
  ------------------------------------- ----------------------------- ---------------- --------------- ------------------------------------------ --------------------------------------------
  Age at CSF, year (SD)                 66.9 (20.2)                   67.6 (8.1)       64.7 (8.8)      66.7 (7.8)                                 0.760
  Male gender (%)                       12 (40%)                      25 (69%)         16 (44%)        25 (66%)                                   0.027
  Disease duration, year (SD)           NA                            2.6 (2.1)        3.7 (1.9)       3.5 (2.4)                                  0.063
  Presence of APOE *ε*4 allele (%)      12 (40%)                      20 (55%)         20 (56%)        13 (34%)                                   0.124
  CSF biomarkers                                                                                                                                  
   Total measurable A*β*42              325.5 (89.2)                  254.3 (114.9)    207.6 (77.4)    286.4 (96.5)                               \<0.001[\*\*](#tf1-1){ref-type="table-fn"}
   Suspended A*β*42                     197.1 (86.5)                  156.2 (92.1)     105.6 (44.4)    177.8 (86.2)                               \<0.001[\*\*](#tf1-1){ref-type="table-fn"}
   Total t-Tau                          54.2 (24.9)                   83.6 (44.1)      120.0 (72.1)    71.1 (37.6)                                \<0.001[\*](#tf1-1){ref-type="table-fn"}
   Suspended t-Tau                      45.7 (27.2)                   72.3 (38.9)      102.8 (65.8)    63.5 (32.6)                                \<0.001[\*\*](#tf1-1){ref-type="table-fn"}
   Total p-Tau~181~                     28.8 (16.2)                   42.4 (20.5)      62.9 (39.3)     27.2 (13.5)                                \<0.001[\*](#tf1-1){ref-type="table-fn"}
   Suspended p-Tau~181~                 25.5 (15.4)                   38.7 (19.3)      55.3 (37.6)     26.9 (12.7)                                \<0.001[\*](#tf1-1){ref-type="table-fn"}
  Biomarker ratio                                                                                                                                 
   t-Tau/total measurable A*β*42        0.180 (0.096)                 0.412 (0.365)    0.628 (0.359)   0.288 (0.220)                              \<0.001[\*\*](#tf1-1){ref-type="table-fn"}
   t-Tau/susA*β*                        0.250 (0.145)                 0.641 (0.516)    1.066 (0.593)   0.462 (0.369)                              \<0.001[\*](#tf1-1){ref-type="table-fn"}
  \# with multi-analyte profiling (%)   14 (47%)                      20 (56%)         20 (56%)        15 (39%)                                   0.123

*P* values shown are from ANOVA at the group level: ^\*^Subjects with AD and MCI differ from subjects with normal cognition or other dementia by ANOVA and post-hoc analysis; ^\*\*^Subjects with AD differ from non-AD subjects by ANOVA and post-hoc analysis (AD, Alzheimer\'s disease; MCI, mild cognitive impairment; FTD, frontotemporal dementia; LBD, Lewy body disease; NPH, normal pressure hydrocephalus). SusA*β* levels were different from total measurable A*β*42 when cases were analyzed according to diagnostic categories (*P* = 0.004 for normal cognition, *P* = 0.004 for MCI, *P* \< 0.001 for AD, *P* = 0.002 for other dementia).

![Correlation between CSF total A*β*42 and susA*β* (*n* = 140). Open circles: subjects with normal cognition; yellow triangle: MCI; black triangle: AD; blue circles: non-AD dementia. CSF, cerebrospinal fluid; MCI, mild cognitive impairment; AD, Alzheimer\'s disease.](acn30002-0131-f3){#fig03}

Reproducibility of suspended and total CSF AD biomarkers
--------------------------------------------------------

To replicate our findings, never-thawed CSF aliquots from the same CSF draw obtained from 20 subjects (see Methods) were shipped to Penn for AD biomarker analysis. Suspended and total measurable CSF A*β*42 values levels correlated strongly between Emory and Penn (*R* = 0.846 and 0.774), as well as % susA*β* (*R* = 0.841).

SusAβ versus total Aβ42 in the calculation of t-Tau/Aβ42 ratio
--------------------------------------------------------------

As susA*β* levels represent approximately half of total A*β*42 levels, the choice of using susA*β* or total measurable A*β*42 level in AD diagnosis can significantly impact the performance of universal cut-off values. We thus examined the corresponding values using total measurable A*β*42 and t-Tau/A*β*42 based on previously published values using the ADNI protocol.[@b28] Notably, the susA*β* of 192 pg/mL corresponds to total A*β*42 of 310 pg/mL, with subjects having concordant A*β*42 status (normal vs. decreased) in 121/140 cases (86.4%). On the other hand, t-Tau/susA*β* ratio of 0.39 corresponds to total t-Tau/A*β*42 ratio of 0.28, with a high concordance rate between the two ratio markers (136/140 cases, or 97.1%).

Effect of a single freeze--thaw cycle on CSF % susAβ
----------------------------------------------------

Most biomarker protocols involve immediate freezing at −80°C until further analysis. As protein solubility can be influenced by temperature, we first tested if freeze--thawing would alter % susA*β*. Compared to % susA*β* values after a single freeze--thaw cycle, keeping the CSF samples at 37°C for up to 2 h between lumbar puncture and analysis resulted in much higher % susA*β* (mean 82.7%, SD 14.5%, *P* = 0.028 by Mann--Whitney *U*-test, Fig.[1A](#fig01){ref-type="fig"}). As care is taken such that CSF samples are not exposed to CO~2~, the standard freezing step involved in long-term storage is likely sufficient to reduce CSF % susA*β*.

Relationship between susAβ and other CSF protein levels
-------------------------------------------------------

Other than temperature, % susA*β* can be influenced by proteins which bind the relatively hydrophobic peptide. To determine which candidate CSF proteins influence % susA*β*, we first determined whether susA*β* levels were influenced by levels of other proteins implicated in AD (apoE, apoJ, *α*-synuclein, and total protein) in a smaller cohort (*n* = 69). The four diagnostic groups did not differ in levels of apoE (*P* = 0.919), apoJ (*P* = 0.724), *α*-synuclein (*P* = 0.629), and total protein (*P* = 0.833). Linear multivariate regression analysis showed that while total measurable CSF A*β*42 levels were only correlated with MCI or AD diagnosis, susA*β* levels were also influenced by levels of apoJ and t-Tau (Table[2](#tbl2){ref-type="table"}). Similarly, % susA*β* was most associated with apoJ (*F* = 26.5, *P* \< 0.001) and t-Tau (*F* = 16.0, *P* \< 0.001) levels, even when age, gender, diagnosis, disease duration, and CSF biomarker (A*β*42, p-Tau~181~, apoE, *α*-synuclein, and total protein) levels were entered into the model.

###### 

Biological factors which influence CSF susA*β* levels

  Factors                B (95% confidence interval)                    *P*
  ---------------------- ---------------------------------------------- ---------
  Total A*β*42 (pg/mL)   0.625 (0.546, 0.705)                           \<0.001
  apoJ (pg/mL)           1.34 × 10^−6^ (0.82 × 10^−6^, 1.86 × 10^−6^)   \<0.001
  t-Tau (pg/mL)          −0.155 (−0.306, −0.005)                        0.043
  Constant               −76.55 (−10931, −43.79)                        \<0.001

In this model, CSF susA*β* levels were entered as the dependent variable, while age, gender, disease duration, presence of APOE4 allele, and biomarker levels (including total A*β*42, total t-Tau, total p-Tau~181~, apoE, apoJ, albumin, and *α*-synuclein) were entered in a stepwise fashion. The final model had a *R*^2^ of 0.841 in predicting CSF susA*β* levels. CSF, cerebrospinal fluid.

We next determined if increased apoJ levels accelerated the return of in vitro susA*β* to in vivo levels, or increased the overall % susA*β*42. We selected subjects with low baseline % susA*β* (median 34%, range 32--49%) to avoid the ceiling effect. Incubating CSF samples at 37°C after freeze--thawing gradually increased % susA*β* over 72 h. When purified apoJ was added at baseline, % susA*β* increased asymptotically over the same period, but to a higher final level (Fig.[4A](#fig04){ref-type="fig"}). Addition of purified apoE and albumin also increased the CSF % susA*β* after 4 h (*P* = 0.029, and *P* \< 0.001, Fig.[4B](#fig04){ref-type="fig"}), but addition of purified *α*-synuclein did not.

![Factors which influence the cerebrospinal fluid (CSF) % susA*β*. (A) Incubation of CSF at 37°C gradually increases the in vitro CSF % susA*β* until it reaches a plateau at 24--72 h, and incubation of CSF at 37°C with additional apoJ increases the asymptotic plateau in a parallel time-dependent fashion. Mixed linear analysis showed that apoJ addition increased the plateau of % susA*β* (*P* = 0.003) but did not alter the rate by which % susA*β* ratio reached the plateau (*P* = 0.426). (B) Fold changes from baseline % susA*β* after addition of A*β*42-interacting proteins. Exogenous apoE, apoJ, and albumin (alb), but not *α*-synuclein (*α*-syn), increases the in vitro CSF % susA*β* after 4 h of incubation at 37°C. ApoJ levels were increased from 46.6*--*62.6 *μ*g/mL, apoE levels were increased from 3.12*--*13.5 *μ*g/mL, total protein levels were increased from 401*--*1207 *μ*g/mL by addition of albumin, and *α*-synuclein levels were increased from 0.65 to 1.05 ng/mL. \**P* \< 0.03 compared to buffer-treated samples.](acn30002-0131-f4){#fig04}

Discussion
==========

CSF biomarkers related to fundamental AD pathology hold great promise in the early and accurate prediction of underlying AD neuropathology, and there is ongoing effort to standardize operating procedures between laboratories to establish universally applicable models of AD diagnosis.[@b10] Here, we report critical in vivo and ex vivo factors associated with a 1.5- to 2-fold difference in measured A*β*42 levels. We observe in a large cohort that the difference between total measurable and susA*β* is most strongly associated with CSF apoJ and t-Tau levels, and % susA*β* can be manipulated by increasing levels of apoJ and apoE. As CSF % susA*β* is influenced by AD-related and AD-unrelated factors, we propose that apparent susA*β* is a much more complex measure than total measurable CSF A*β*42 and does not directly represent the total A*β*42 abundance.

Reproducible measurements of CSF AD biomarkers, especially A*β*42, have been a major challenge in their translation to clinical use.[@b10] As we report here, seemingly minute differences in standard operating procedures can result in large differences in the measured biomarker levels. Since CSF AD biomarkers are already susceptible to preanalytical factors such as diurnal variation[@b29] and collection tube material,[@b30] it was not surprising that preanalytical protocol variations following lumbar puncture can result in approximately twofold difference in A*β*42 levels. The biggest alterations in A*β*42 levels may have come from the standard freeze--thawing cycle universally applied to biomarker studies. Because clinical trials targeting A*β* clearance or production measure susA*β* levels[@b31],[@b32] to determine whether there is global A*β* reduction and have unknown effects on A*β*-binding proteins, we propose that total measurable A*β*42 levels better reflect total A*β*42 "load" than susA*β*.

SusA*β* levels were previously associated with cerebral amyloid deposition, hippocampal atrophy, and longitudinal cognitive decline, and the strong correlation between suspended and total A*β*42 suggests that total A*β*42 would have the same predictive power. At the same time, the reduction in CSF A*β*42 level is further accentuated by AD diagnosis and increased CSF t-Tau levels, which may make CSF susA*β*42 a more clinically useful diagnostic marker despite its "non-physiologic" nature. Because % susA*β* is associated with increasing levels of A*β*-binding proteins, susA*β* may represent the pool of protein-bound peptides available for lipoprotein-mediated clearance. The association between increasing apoE, apoJ, and albumin levels with higher % susA*β* at 37°C is in keeping with the observation of higher susA*β* without freeze--thawing than with freezing, and suggests that A*β*42 may lose its physiologic interaction with its binding proteins after freezing and may be more prone to aggregation.[@b33] With the duration of vortex representing the major difference between ADNI and Vortex protocols, this binding likely is promoted by prolonged vigorous vortexing. Vigorous vortexing prior to plate loading likely promotes this protein--protein interaction, and the interaction is likely saturable as nonphysiologic levels of apoE and apoJ could not bring % susA*β* to 100%. If apoE-directed therapy[@b34],[@b35] is used in AD with or without A*β*-directed therapies, the most robust biomarker profile would then consist of susA*β*, total measurable Ab, as well as t-Tau, apoE, and apoJ rather than any single biomarkers alone.

This study has a number of limitations. Very few of the 140 subjects had autopsy confirmation or amyloid imaging, which makes it challenging for us to derive autopsy-correlated biomarker cut-off values beyond those which correspond to previously reported values.[@b28] We did not determine the influence of exact timing of day on % susA*β*. We only measured a subset of abundant A*β*42 interacting proteins, and other CSF proteins may alter % susA*β* ratios in parallel to or in conjunction with apoJ and apoE. We did not provide direct evidence that exogenous apoE or apoJ directly bound to CSF A*β*42 to enhance its solubility, even though apolipoproteins are known to interact with A*β* and may prevent its aggregation[@b22],[@b33],[@b36],[@b37] We also did not use gamma-secretase inhibitors to account for de novo production of A*β*42 peptides, but gamma-secretase activity has not been reported in CSF and presenilin 1 and 2 fragments detected in CSF are felt to represent nonspecific aggregation rather than gamma-secretase complexes.[@b38] We propose that alterations in CSF % susA*β* are due to technical and biological factors, and susA*β*42 levels, t-Tau/susA*β*42 ratio, as well as their impact on other biological correlates of AD should be interpreted with care because these in vitro measures reflect amyloid protein\'s total abundance as well as its dynamic interactions with other AD-associated proteins and AD itself.
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